Treatment of metastatic tumors with engineered adenoviruses that replicate selectively in tumor cells is a new therapeutic approach in cancer. Systemic administration of these oncolytic adenoviruses lack metastatic targeting ability. The tumor stroma engrafting property of intravenously injected mesenchymal stem cells (MSCs) may allow the use of MSCs as cellular vehicles for targeted delivery. In this work, we study the safety and the efficacy of infusing autologous MSCs infected with ICOVIR-5, a new oncolytic adenovirus, for treating metastatic neuroblastoma. Four children with metastatic neuroblastoma refractory to front-line therapies received several doses of autologous MSCs carrying ICOVIR-5, under an approved preliminary study. The tolerance to the treatment was excellent. A complete clinical response was documented in one case, and the child is in complete remission 3 years after this therapy. We postulate that MSCs can deliver oncolytic adenoviruses to metastatic tumors with very low systemic toxicity and with beneficial antitumor effects.
Introduction
Neuroblastoma (NB) is the most common extracranial solid tumor in children. Intensive chemotherapy and resection of the primary tumor (in good responders) followed by high-dose chemotherapy with autologous hematopoietic rescue, is the accepted treatment for metastatic NB. Despite intensive multimodal treatment approaches, the prognosis of refractory metastatic NB is very poor. Experimental therapies have not improved the long-term survival of this relentless malignant disease. 1 A new modality of treatment based on engineered adenoviruses that replicate selectively in tumor cells, is currently being considered against metastatic tumors.
2
Most of the advances on oncolytic adenoviruses have been related to replication selectivity through mutations or promoter insertions. However, a major hurdle remains to reach metastases upon systemic administration. To overcome the lack of tumor-targeting properties of adenoviruses, the tumor stroma engrafting property of intravenously (i.v.) injected mesenchymal stem cells (MSCs) has been used. 3 MSCs infected with adenoviral vectors carry their load efficiently to metastatic tumors. 4 The IV infusion of MSCs loaded with oncolytic adenoviruses into animals with metastasis resulted in the destruction of metastasis without systemic toxicities. 5 These and other promising results have shown the feasibility of using MSCs as cell vehicles. [6] [7] [8] [9] We have already published our experience with oncolytic adenoviruses. [10] [11] [12] ICOVIR-5 is an oncolytic adenovirus with essential virus genes controlled by an E2F-responsive promoter. 11, 12 This transcriptional regulation, coupled to the inability of this virus to separate E2F from RB, restricts the replication of ICOVIR-5 to cells with an activated RB pathway, a hallmark of cancer cells.
We have performed an exploratory study for treating children with refractory metastatic NB based on the infusion of CELYVIR: autologous MSCs infected with ICOVIR-5, an oncolytic adenovirus that selectively replicate in cancer cells. 11, 12 We describe the results of our initial clinical experience in this paper.
Patients and methods

Patients
Four patients received treatment with CELYVIR in this exploratory study, approved by the local Ethic Committee for Clinical Research. Clinical characteristics of the patients are shown in Table 1 .
Adenoviral vectors and ICOVIR-5
Vectors AdTL (AdGFPLuc) and AdTLRGD (Ad5 LucRGD) have been previously described. 13, 14 These vectors derive from Ad5 and contain a green fluorescent protein and a luciferase expression cassette under constitutive cytomegalovirus promoters replacing the E1 region of adenovirus. ICOVIR-5 has been extensively described elsewhere.
11,12
Human MSCs cultures After obtaining informed consent, BM aspirates were obtained in heparinized tubes. Mononuclear cells were isolated by Ficoll density centrifugation (400 g, 25 min, 20 1C), washed twice with phosphate buffer by sedimentation (300 g, 5 min, room temperature), the cells were resuspended in MSC medium (DMEM plus 10% FCS, 2 mM glutamine, 10 U/L penicillin, 10 mg ml -1 streptomycin, all from Sigma, St Louis, MO) and seeded onto culture flasks (Nunc, Roskilde, Denmark) at 1.5 Â 10 5 cells per cm 2 and allowed to adhere (24 h). Non-adherent hematopoietic stem cells were removed by washing twice with PBS (10 ml). MSC were cultured (37 1C, 5% CO 2 ) in MSC medium and passaged when they reached 85% confluence (twice weekly). Cells were treated with 0.5% trypsin plus 0.2% EDTA (5 min), washed with culture medium, sedimented (300 g, 10 min, room temperature) and plated ( 
Flow cytometry
Flow cytometry analysis (FACS Canto II cytometer, Becton Dickinson Bioscience, Franklin Lakes, NJ) was used for detecting blood circulating lymphocytes. Briefly, peripheral blood (100 ml) was stained with antihuman CD45, CD3, CD4, CD8, CD19 and CD56 (BD Bioscience) for 20 min, and then red blood cells were lysed by incubating with 1 ml of lysis solution (Quick Lysis, VITRO, Spain). For each analysis, 20 000 events were collected and analyzed with the FACS Diva software (BD Bioscience).
Flow cytometry analysis was also used for assessing the viability of NB cells after coculturing them with MSCs carrying ICOVIR-5. Harvested cells were stained with antiGD2 (Disialoganglioside GD2, US Biological, Swampscott, MA) and antiCD56 (BD Biosciences) monoclonal antibodies, to distinguish NB cells from MSCs. The Annexin-V/7AAD kit (from BD Bioscience) was used to detect apoptotic NB cells, following manufacturer's instructions. For each analysis, 20 000 events were collected and analyzed with the FACS Diva software (BD Bioscience).
Preparation of CELYVIR
Autologous mononuclear cells from patients with metastatic neuroblastoma were isolated from bone marrow aspirates by Ficoll density centrifugation and allowed to adhere in cell culture flasks. After the third passage, we obtained a homogeneous MSC culture, as described. 15 Before infusion, MSCs were inactivated by x-ray irradiation (30 Gy), and then infected with ICOVIR-5 at an MOI of 200 p.f.u. per cell. This dose was selected as the minimal dose to achieve complete cytopathic effect, seen 72 h after viral infection. Infection was allowed for 2 h, and then the cells were washed and resuspended in saline (Fresenius Kabi Espan˜a, Barcelona, Spain) with 2% human serum albumin (Grifols, Barcelona, Spain). CELYVIR preparations were infused through a central line. We saved an aliquot of each CELYVIR infusion, plated them and verified the expected cytopathic effect within 72 h.
Clinical outcome studies after CELYVIR infusions Children were closely followed-up after CELYVIR infusions. We controlled renal function (serum creatinine, urea, sodium, potassium and chloride), liver function (serum bilirubin, gamma glutamiltransferase, alkaline fosfatase and transaminases), white blood (differential count), red blood cell and platelets. Twice weekly we searched for ICOVIR-5 in serum and urine samples using a PCR method, 17 and for seroconversion 18 by the complement fixation method. The electron microscopy study was done as described elsewhere. 19 We weekly quantitated the peripheral blood lymphocytes subpopulations by flow cytometry.
Results
Human MSCs allowed efficient ICOVIR-5 replication
Human MSCs may be used as cell carriers for oncolytic adenoviruses if they are permissive for infection and allow viral replication. We tested these two characteristics in vitro. We first evaluated the efficacy of adenoviral vectors for infecting hMSC cultures. Figure 1a shows results of transduction efficiency of AdTL vs AdTLRGD in hMSCs. Even with relatively low amount of viral loads, hMSCs were infected at very high rates when using AdTLRGD adenovirus, in contrast with AdTL. We next evaluated the ability of hMSCs to allow adenoviral replication. Figure 1b shows the production of viral particles recovered in the supernatants of hMSCs infected with Ad-wt or with ICOVIR-5. The epithelial lung carcinoma cell line A549 is highly permissive for adenoviral replication and served as control. Seventytwo hours after infection we could recover up to 1.3x10 7 p.f.u. of ICOVIR-5 from 3x10 4 infected hMSCs (a burst size of 430 p.f.u. per infected cell). Although this is significantly lower than the burst size in A549 cells, it clearly showed that hMSCs were permissive for ICOVIR-5 replication.
In the light of these results we next tested the infectivity and replication of ICOVIR-5 in clinically relevant MSC cultures. We set up MSC cultures from marrow aspirates of four patients with metastatic refractory NB. Cultures were passed three times before using the cells for experimental procedures. We confirmed that the cultures contained human MSCs (and not neuroblasts) by flow cytometry and by assessing the differentiation capacity to adipose and bone tissues, as described (15 and Figure 2a) . Aliquots of MSCs were infected with ICOVIR-5 at different MOIs, and the cytopatic effect was assessed 72 h after infection. ICOVIR-5 infected and completely eliminated the MSCs at 200 p.f.u., but the cytopatic effect could be seen at lower doses (Figure 2b) . Therefore, the infectivity and permissivity of hMSCs for ICOVIR-5 implied that this approach could be used for systemically delivering an oncolytic adenovirus to children with refractory metastatic tumors, that is, metastatic NB. CELYVIR is the acronymous we use to name hMSCs infected with ICOVIR-5.
CELYVIR co-cultured with neuroblastoma cells resulted in killing of the tumor cells Human MSCs may be used as cell carriers for oncolytic adenoviruses if they successfully deliver the viruses into the tumor cells, resulting in the death of the latter. We next studied whether ICOVIR-5 produced within hMSCs would kill NB cells in an in vitro coculture system. CELYVIR was prepared as explained, and then mixed with NB cells at different cell-cell ratios. NB cells infected with ICOVIR-5 at an MOI of 200 p.f.u. per cell served as controls. Five days later we killed the cocultures and assessed the viability of NB cells by a flow cytometry assay. MSCs and NB were distinguished by GD2 and CD56 expression levels, and apoptotic NB cells were identified as positive for Annexin-V. Results shown in Figure 3 were obtained with an NB cell line derived from a primary tumor obtained from a patient with metastatic NB. Comparable results were obtained with the LAN1 cell line (not shown). Figure 3 shows that ICOVIR-5 is effective at killing NB cells (control group). In addition, coculturing CELYVIR with NB cells resulted in the death of NB cells. The oncolytic effect of ICOVIR-5 was more vigorous when NB cells were directly infected (Supplementary Figure SP1 ), but it was also significant in the cocultures. Interestingly, irradiation of the hMSCs before infection (as we did for preparing CELYVIR) had no 
CELYVIR therapy and follow-up
Four patients received treatment with CELYVIR in this exploratory study. Clinical characteristics of the patients are shown in Table 1 . All patients had a refractory stage IV neuroblastoma and they had received at least two front-line multichemotherapy treatments before being elected for CELYVIR. All patients but UPN no. 1 had undergone an autologous transplant as part of the multimodal therapy protocol.
CELYVIR infusions were administered depending upon MSCs availability and tolerance. All patients received at least two CELYVIR infusions. Autolimited fever was seen in all patients but UPN no. 3. UPN no. 4 presented a threefold increase in the levels of hepatic alanine aminotransferase after the first infusion that returned to basal levels within 96 h. The presence of ICOVIR-5 was documented both by PCR, 17 antiadenovirus-IgG levels, 18 and electronic microscopy methods, 19 and was positive by at least one assay in all patients. We detected ICOVIR-5 adenovirus in a marrow aspirate from UPN no.2 5 days after the second CELYVIR infusion (Supplementary Figure SP2) . By that time, the virions should correspond to the in vivo secondary infection of marrow cells and showed that CELYVIR carried ICOVIR-5 to areas with metastasis. We studied the immune peripheral blood cells periodically after CELYVIR infusions by flow cytometry. We found an increase in lymphocyte populations, mostly CD8T cells (Figure 4 (Figure 5, right) . All tests done after the last infusion showed no evidence of metastatic disease ( Table 2 ). The clinical response was catalogued as of very good partial remission, and so the standard consolidation therapy was given. High-dose chemotherapy with busulphan and melphalan followed by autologous hematopoietic rescue was performed 2 months after the last CELYVIR infusion, with uneventful outcome. He is now in complete remission 36 months after the first CELYVIR treatment, and more than 4 years after diagnosis.
Discussion
The main objective of this exploratory study was gathering information about safety with the use of CELYVIR for metastatic pediatric cancers. MSCs have been already used in clinical trials or pilot studies and single cases [20] [21] [22] [23] [24] [25] [26] [27] [28] for several human diseases: osteogenesis Systemic delivery of oncolytic adenoviruses J García-Castro et al imperfecta, multiple sclerosis, acute myocardial infarctation, graft versus host disease and others. MSCs were directly implanted or IV infused, with good tolerance. There are also clinical experiences with the use of IVinfused adenovirus in cancer gene therapy, 2 and although dose-limiting toxicity was not reported, there were dosedependent fevers, vomits, nauseas, and chills and transaminitis at the highest doses. The combination of MSCs and oncolytic adenoviruses has not been reported to date in a clinical setting. Our therapy did not have any severe hematological, neurological or metabolic side effect except for autolimited fever or mild transaminase increase in one patient. This toxicity is clearly milder than that seen with many chemo and radiotherapy treatments. It supports the hypotheses that adenoviral toxicity is localized to the anatomical sites where MSCs home to, reaching high concentrations at those areas but not systemically. We inactivated MSCs before infusion as an important safety measure, because it has been suggested that infused viable MSCs may enhance metastases, 29 and irradiation does not affect adenovirus replication (Post et al., 30 and Figure 3 ). We did not find any sign of tumor growth nor disease progression related to the infusion of irradiated and infected MSCs in our patients.
In addition to a low toxicity, we show here the potential clinical benefits of delivering oncolytic adenoviruses within MSCs in patients with refractory cancer. It has been shown that MSCs target metastasis, allow adenoviral replication, and may protect the oncolytic virus from neutralizing antibodies and innate immune responses for the first hours immediately after IV infusion. 3, 6, 7 Our cellular vehicle should persist for 48-72 h after infusion, based on in vitro data. Animal models have shown that MSCs homing into metastases occurs within this time window. 6, 7 The clinical effect seen in UPN no. 1 may be explained by either or a combination of two distinct mechanisms. First, direct oncolysis: CELYVIR delivered ICOVIR-5 to the sites where metastatic NB was present (Supplementary Figure SP2) , and from there, progressive viral infection of NB cells likely followed, reaching high concentrations at the sites of metastases, but not elsewhere. ICOVIR-5 is an oncolytic adenovirus with essential virus genes controlled by an E2F-responsive promoter. 11, 12 This transcriptional regulation, coupled to the inability of this virus to separate E2F from RB, restricts the replication of ICOVIR-5 to cells with an activated RB pathway, a hallmark of cancer cells. The replication of ICOVIR-5 in ex vivo proliferating MSCs was expected, as proliferating cells contain free E2F to activate ICOVIR-5. Accordingly, aliquots of non-infused CELYVIR showed a characteristic cytopatic effect upon in vitro incubation for 72 h (Figure 2 ). The in vivo oncolytic process in NB cells should progress until tumor disappearance or, more likely, an immune response eliminates the virus and the infected cells in situ. In these patients, virus was detected only in few of many assays in serum or urine samples, indicating a low level of systemic release. This explains the almost complete absence of systemic toxicity. The second therapeutic mechanism postulated may be immune mediated. Dying NB cells may release tumor antigens that are processed by dendritic cells in the presence of the danger signals associated with viral infection. 31 This leads to maturation of dendritic cells that migrate to draining lymph nodes and present antigens to T lymphocytes, away from the inhibitory environment of the tumor. In this regard, our treatment would act as a vaccination strategy. The fact that repeated infusions of CELYVIR were followed by increasing numbers of circulating cytotoxic T lymphocytes in UPN no. 1, strongly suggest an immune response (Figure 4) . It is tempting to speculate that ICOVIR-5 acted as an adjuvant in establishing an antitumor immune response. This phenomenon has been already suggested in the field of tumor virotherapy. 32 We did not have means to test for the presence of specific anti-tumor cytotoxic T lymphocytes after the therapy, because primary tumor cells were lacking. However, the observed changes in CD8 þ lymphocytes, the extensive disease at the time of treatment, and the evidence of response after the second round of treatment, suggest that the major therapeutic mechanism may be an immune response secondary to the inflammatory oncolysis produced by ICOVIR-5. Preclinical models have shown that virus-mediated oncolysis can spark antitumor res-
PRE-CELYVIR
POST-CELYVIR ponses. 33 In this regard, it could be important to note UPN no. 1 had not undergone a hematopoietic transplant, and his immune repertoire at the time of CELYVIR treatment should have been richer than in transplanted patients.
An important point in the outcome of UPN no. 1 from a practical clinical point of view was the fact that the initial very good partial remission achieved with CELYVIR was followed by the current most accepted consolidation therapy for good responder NB stage IV. 34 It has been reported that the combination therapy (virotherapy þ chemotherapy) resulted in synergistic efficacy in some patients. 35 This patient might be a good example on how systemic virotherapy can be used in combination with standard multimodal protocols for metastatic cancers.
In our 20 years of clinical experience with more than 120 cases of NB, this is the first stage IV refractory NB that achieved a complete remission with an experimental therapy. We will start defining the potential benefits of CELYVIR for metastatic neuroblastoma and other pediatric tumors refractory to two or more standard lines of therapy in a phase I clinical (EudraCT number 2008-000364-16).
